Novocure (NVCR) Stock Forecast & Price Target

NovoCure is expected to see an increase in their probability of success (POS) for pancreatic cancer from 70% to 100% following regulatory approval, leading to an increase in their price target to $47. In 4Q25, NovoCure's revenue beat expectations with strong domestic sales of Optune Gio attributed to a higher G2N benefit and an increase in active patients on the device. However, the lung opportunity remains uncertain with limited traction due to competition from targeted therapies and short treatment duration. Future catalysts include topline data from the PANOVA-4 and TRIDENT studies, as well as regulatory decisions for PMA applications in pancreatic cancer and brain metastases from NSCLC.

NovoCure is heavily dependent on its flagship product, Optune, for revenue, with limited sales growth seen in other indications. While the launch of Optune in locally advanced pancreatic cancer could provide a boost to sales, the company's high reliance on one product puts it at risk if sales do not meet expectations or if there are clinical failures. Additionally, the company's strategy of educating non-physician staff and building on momentum from previous approvals may not be enough to drive significant growth in a competitive market.